share_log

Los Angeles Capital Management LLC Has $1.34 Million Holdings in Meridian Bioscience, Inc. (NASDAQ:VIVO)

Los Angeles Capital Management LLC Has $1.34 Million Holdings in Meridian Bioscience, Inc. (NASDAQ:VIVO)

洛杉矶资本管理公司持有134万美元的子午线生物科学公司股份(纳斯达克代码：VIVO)
Defense World ·  2022/08/11 06:21

Los Angeles Capital Management LLC lessened its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) by 11.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 51,531 shares of the company's stock after selling 6,740 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.12% of Meridian Bioscience worth $1,338,000 at the end of the most recent quarter.

洛杉矶资本管理有限责任公司最近提交给美国证券交易委员会的文件显示，该公司今年第一季度将其在纳斯达克(Sequoia Bioscience，Inc.)股票的持仓比例降低了11.6%。该公司在本季度出售了6,740股后，持有51,531股该公司股票。截至最近一个季度末，洛杉矶资本管理公司拥有Meridian Bioscience公司约0.12%的股份，价值1,338,000美元。

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VIVO. Advisor Group Holdings Inc. grew its position in shares of Meridian Bioscience by 6.1% during the 1st quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company's stock worth $464,000 after buying an additional 940 shares during the period. Teton Advisors Inc. grew its position in shares of Meridian Bioscience by 6.4% during the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company's stock worth $510,000 after buying an additional 1,500 shares during the period. Horan Securities Inc. acquired a new stake in shares of Meridian Bioscience during the 4th quarter worth approximately $33,000. Prospera Financial Services Inc acquired a new stake in shares of Meridian Bioscience during the 1st quarter worth approximately $42,000. Finally, Rhumbline Advisers grew its position in shares of Meridian Bioscience by 1.4% during the 4th quarter. Rhumbline Advisers now owns 126,390 shares of the company's stock worth $2,578,000 after buying an additional 1,778 shares during the period. Institutional investors and hedge funds own 94.72% of the company's stock.

其他一些机构投资者和对冲基金也增持或减持了vivo的股份。Advisor Group Holdings Inc.在第一季度将其在Meridian Bioscience的股票头寸增加了6.1%。Advisor Group Holdings Inc.在此期间又购买了940股，现在拥有16,453股该公司股票，价值46.4万美元。Teton Advisors Inc.在第四季度将其在Meridian Bioscience的股票头寸增加了6.4%。Teton Advisors Inc.在此期间又购买了1,500股，现在持有25,000股该公司股票，价值51万美元。霍兰证券公司在第四季度收购了Meridian Bioscience的新股份，价值约3.3万美元。普罗斯佩拉金融服务公司在第一季度收购了Meridian Bioscience的新股份，价值约42,000美元。最后，Rhumbline Advisers在第四季度将其在子午线生物科学公司的股票头寸增加了1.4%。在此期间，Rhumbline Advisers又购买了1,778股，现在拥有126,390股该公司股票，价值2,578,000美元。机构投资者和对冲基金持有该公司94.72%的股票。

Get
到达
Meridian Bioscience
子午线生物科学
alerts:
警报：

Meridian Bioscience Stock Performance

子午线生物科学股票表现

NASDAQ VIVO opened at $32.75 on Thursday. The company has a fifty day simple moving average of $30.77 and a 200 day simple moving average of $27.32. Meridian Bioscience, Inc. has a 12-month low of $17.20 and a 12-month high of $34.38. The company has a current ratio of 3.85, a quick ratio of 2.60 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.43 billion, a P/E ratio of 33.08 and a beta of 0.28.

纳斯达克VIVO周四开盘报32.75美元。该公司的50日简单移动均线切入位为30.77美元，200日简单移动均线切入位为27.32美元。Meridian Bioscience，Inc.的股价为17.20美元，为12个月低点，12个月高位为34.38美元。该公司的流动比率为3.85，速动比率为2.60，债务权益比率为0.07。该公司市值14.3亿美元，市盈率为33.08倍，贝塔系数为0.28。

Insider Activity at Meridian Bioscience

子午线生物科学的内部活动

In related news, CEO John P. Kenny sold 13,559 shares of Meridian Bioscience stock in a transaction on Friday, June 24th. The shares were sold at an average price of $30.00, for a total value of $406,770.00. Following the completion of the sale, the chief executive officer now owns 265,131 shares of the company's stock, valued at approximately $7,953,930. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Meridian Bioscience news, CEO John P. Kenny sold 13,559 shares of the firm's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $406,770.00. Following the transaction, the chief executive officer now directly owns 265,131 shares in the company, valued at approximately $7,953,930. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John P. Kenny sold 44,651 shares of the firm's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $29.72, for a total value of $1,327,027.72. Following the transaction, the chief executive officer now owns 265,131 shares in the company, valued at $7,879,693.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,647 shares of company stock valued at $3,600,868. 2.30% of the stock is owned by company insiders.
在相关新闻中，首席执行官约翰·P·肯尼在6月24日(星期五)的一次交易中出售了13,559股Meridian Bioscience股票。这些股票的平均价格为30.00美元，总价值为406,770.00美元。出售完成后，首席执行官现在拥有265,131股公司股票，价值约7,953,930美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过美国证券交易委员会网站访问该文件。在Meridian Bioscience的其他消息中，首席执行官约翰·P·肯尼在6月24日星期五的一次交易中出售了13,559股该公司的股票。该股以30.00美元的平均价格出售，总成交金额为406,770.00美元。交易完成后，这位首席执行官现在直接拥有该公司265,131股，价值约7,953,930美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超级链接获得。此外，首席执行官约翰·P·肯尼在6月22日星期三的一次交易中出售了44,651股公司股票。这些股票的平均价格为29.72美元，总价值为1,327,027.72美元。交易完成后，这位首席执行官现在拥有该公司265,131股，价值7879,693.32美元。此次拍卖的披露信息可在此处找到。在过去的90天里，内部人士卖出了119,647股公司股票，价值3,600,868美元。2.30%的股份由公司内部人士持有。

Analyst Upgrades and Downgrades

分析师升级和下调评级

VIVO has been the subject of several recent analyst reports. StockNews.com downgraded shares of Meridian Bioscience from a "buy" rating to a "hold" rating in a research report on Tuesday. William Blair downgraded shares of Meridian Bioscience from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 7th. Finally, HC Wainwright downgraded shares of Meridian Bioscience from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $30.00 to $34.00 in a research report on Friday, July 8th.

Vivo是最近几份分析师报告的主题。在周二发布的一份研究报告中，StockNews.com将Merdian Bioscience的股票评级从买入下调至持有。在7月7日周四的一份研究报告中，威廉·布莱尔将子午线生物科学公司的股票评级从“跑赢大盘”下调至“市场表现”。最后，在7月8日星期五的一份研究报告中，HC Wainwright将Meridian Bioscience的股票评级从买入下调至中性，并将该股的目标价从30.00美元上调至34.00美元。

Meridian Bioscience Profile

子午线生物科学概况

(Get Rating)

(获取评级)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Meridian Bioscience，Inc.是一家生命科学公司，主要开发、制造、分销和销售诊断试剂盒，主要用于胃肠道和呼吸道传染病以及全球范围内的血铅水平升高。该公司通过诊断和生命科学部门开展业务。诊断部门提供测试平台，包括Revogene品牌下的实时PCR扩增；Alethia品牌下的等温DNA扩增；Curian品牌下使用荧光化学的侧向流动免疫分析；免疫卡和免疫卡STAT下的快速免疫分析！品牌；Premier品牌的酶联免疫检测；LeadCare品牌的阳极溶出伏安法；以及H.

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
  • Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
  • The 2 Dow Stocks with Decade-Long Win Streaks on the Line
  • Could Rite Aid Be an Acquisition Target, Again?
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • 免费获取StockNews.com关于子午线生物科学的研究报告(Vivo)
  • 大型和小型石油和天然气类股盈利后反弹
  • 连续十年上涨的两只道指股票
  • Rite Aid会再次成为收购目标吗？
  • 投资石油股票的方式和原因
  • 投资黄金股票的方式和原因

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating).

想看看其他对冲基金持有哪些VIVO吗？请访问HoldingsChannel.com以获取Merdian Bioscience，Inc.(纳斯达克：VIVO-GET Rating)的最新13F备案和内幕交易信息。

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

接受《子午线生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收对Meridian Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发